This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact ­information

Infectious disease

Tuberculosis

G protein-coupled receptor 109A (GPR109A; HM74A)

A study in macrophages and mice suggests inhibiting GPR109A could help treat tuberculosis. In Mycobacterium tuberculosis-infected macrophages, small interfering RNA knockdown of the host protein GPR109A decreased the accumulation of lipid bodies, which are a nutrient source for the bacteria, compared with no knockdown. In mice infected with M. tuberculosis, the GPR109A inhibitor mepenzolate bromide decreased pathogen loads in the lung, liver and spleen compared with vehicle. Next steps could include developing GPR109A inhibitors with better pharmacokinetics and testing the longer-term effects of inhibiting GPR109A in animal models of M. tuberculosis infection.

SciBX 5(49); doi:10.1038/scibx.2012.1287
Published online Dec. 20, 2012

Patent and licensing status unavailable

Singh, V. et al. Cell Host Microbe; published online Nov. 15, 2012;
doi:10.1016/j.chom.2012.09.012
Contact: Kanury V.S. Rao, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
e-mail:

kanury@icgeb.res.in